MRI Volumetrics for Risk Stratification of Vision Loss in Optic Pathway Gliomas Secondary to NF1
Abstract
Our overall objective is to develop and validate a novel quantitative MRI analysis software application that will enable: 1) identifying children who are at the greatest risk for vision loss from their NF1-OPG; and 2) making treatment decisions based on accurate evaluation of disease progression and response to therapy. Currently, we have completed Tasks 1, 2 and 3 (Aim 1) and Task 4-5 (Aim 2). The remaining tasks in Aim 3 as listed in the SOW were impacted by the COVID19 pandemic, but have been addressed and should readily be completed during our no cost extension. We continue to refine and analyze how we use the different MRI features to create our predictive algorithm. While we have produced some encouraging and supportive results, we do not want to publish these results until we can confirm we have done due diligence and complete the most rigorous analysis. Lastly, as the coPI of the NF1-OPG natural history study (D3 and D4 cohorts), I can confirm will have a complete data set needed to complete the Aim 3 analysis during the NCE. We have not made any significant changes to our study plan.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2022
- Accession Number
- AD1190404
Entities
People
- Robert A. Avery
Organizations
- Children's Hospital of Philadelphia